Rusfertide vs Thymosin Alpha-1
Overview
Rusfertide is primarily a weight management & metabolic peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Rusfertide and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Rusfertide | Thymosin Alpha-1 | |
|---|---|---|
| Category | Weight Management & Metabolic | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 19-108 mg | 1.6-3.2 mg |
| Frequency | once weekly, subcutaneous | twice-weekly |
| Reported benefits | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Rusfertide is categorised under Weight Management & Metabolic, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Rusfertide: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Rusfertide and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Rusfertide and Thymosin Alpha-1?
- Rusfertide is primarily a weight management & metabolic peptide, while Thymosin Alpha-1 is used for healing & recovery. Rusfertide is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Rusfertide and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Rusfertide and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Rusfertide or Thymosin Alpha-1 FDA-approved?
- Rusfertide is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Rusfertide — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references